Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [17]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10666-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10666-1-AP, RRID:AB_2166973
- Product name
- PMM2 antibody
- Antibody type
- Polyclonal
- Description
- PMM2 antibody (Cat. #10666-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Lipo-Glc-1,6-P(2): A Bioprecursor Prodrug for Phosphomannomutase-2 Congenital Disorder of Glycosylation.
PMM2 interacts with TRIM28 to recruit E2F4 and promote KIFC3-mediated tumor glycolysis and colorectal cancer progression.
Immunopathology in PMM2-CDG: Defective glycosylation impact in the TNFα -TNFR1 signalling pathway.
Establishing an auxin-inducible GFP nanobody-based acute protein knockdown system to mimic hypomorphic mutations during early medaka embryogenesis.
AAV-based gene replacement therapy prevents and halts manifestation of abnormal neurological phenotypes in a novel mouse model of PMM2-CDG.
Beneficial effects of Glc-1,6-P(2) modulation on mutant phosphomannomutase-2.
HepG2 PMM2-CDG knockout model: A versatile platform for variant and therapeutic evaluation.
AAV9-based PMM2 gene replacement augments PMM2 expression and improves glycosylation in primary fibroblasts of patients with phosphomannomutase 2 deficiency (PMM2-CDG).
Complex metabolic disharmony in PMM2-CDG paves the way to new therapeutic approaches.
Exploring the glycolytic cross-talk genes between inflammatory bowel disease and colorectal cancer.
N-Glycosylation Deficiency Reduces the Activation of Protein C and Disrupts Endothelial Barrier Integrity.
Fatal outcome after heart surgery in PMM2-CDG due to a rare homozygous gene variant with double effects.
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Novel variants and clinical symptoms in four new ALG3-CDG patients, review of the literature, and identification of AAGRP-ALG3 as a novel ALG3 variant with alanine and glycine-rich N-terminus.
Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2.
Lack of phosphomannomutase 2 affects Xenopus laevis morphogenesis and the non-canonical Wnt5a/Ror2 signalling.
Changes in the striatal proteome of YAC128Q mice exhibit gene-environment interactions between mutant huntingtin and manganese.
Sodano F, Monticelli M, Hay Mele B, Rolando B, Lazzarato L, De Simone A, Andrisano V, Paris D, Rimoli MG, Cubellis MV, Andreotti G
IUBMB life 2026 Apr;78(4):e70101
IUBMB life 2026 Apr;78(4):e70101
PMM2 interacts with TRIM28 to recruit E2F4 and promote KIFC3-mediated tumor glycolysis and colorectal cancer progression.
Peng Z, Ma B, Song Z, Zhao Y, Yang Y, Liu Y, Li C, Zhang Y
Oncogene 2026 Apr;45(12):1145-1160
Oncogene 2026 Apr;45(12):1145-1160
Immunopathology in PMM2-CDG: Defective glycosylation impact in the TNFα -TNFR1 signalling pathway.
Pascoal C, Granjo P, Kodríková R, Falcão M, Santos AC, Teodoro I, Pakanová Z, Nemčovič M, Mucha J, Castro-Caldas M, Grosso AR, Dos Reis Ferreira V, Videira PA
Frontiers in immunology 2025;16:1655354
Frontiers in immunology 2025;16:1655354
Establishing an auxin-inducible GFP nanobody-based acute protein knockdown system to mimic hypomorphic mutations during early medaka embryogenesis.
Pakari K, Jakab S, Rasch J, Salvador ES, Wittbrodt B, Thiel C, Wittbrodt J, Thumberger T
Biology open 2025 Nov 15;14(11)
Biology open 2025 Nov 15;14(11)
AAV-based gene replacement therapy prevents and halts manifestation of abnormal neurological phenotypes in a novel mouse model of PMM2-CDG.
Zhong ML, Lai K
Gene therapy 2025 May;32(3):246-254
Gene therapy 2025 May;32(3):246-254
Beneficial effects of Glc-1,6-P(2) modulation on mutant phosphomannomutase-2.
Monticelli M, Paris D, Monti MC, Morretta E, Pakanova Z, Nemcovic M, Kodrikova R, Cubellis MV, Andreotti G
Biochimica et biophysica acta. Molecular cell research 2025 Jun;1872(5):119948
Biochimica et biophysica acta. Molecular cell research 2025 Jun;1872(5):119948
HepG2 PMM2-CDG knockout model: A versatile platform for variant and therapeutic evaluation.
Vilas A, Briso-Montiano Á, Segovia-Falquina C, Martín-Martínez A, Soriano-Sexto A, Gallego D, Ruiz-Montés V, Gámez A, Pérez B
Molecular genetics and metabolism 2024 Sep-Oct;143(1-2):108538
Molecular genetics and metabolism 2024 Sep-Oct;143(1-2):108538
AAV9-based PMM2 gene replacement augments PMM2 expression and improves glycosylation in primary fibroblasts of patients with phosphomannomutase 2 deficiency (PMM2-CDG).
Zhong M, Balakrishnan B, Guo AJ, Lai K
Molecular genetics and metabolism reports 2024 Mar;38:101035
Molecular genetics and metabolism reports 2024 Mar;38:101035
Complex metabolic disharmony in PMM2-CDG paves the way to new therapeutic approaches.
Himmelreich N, Kikul F, Zdrazilova L, Honzik T, Hecker A, Poschet G, Lüchtenborg C, Brügger B, Strahl S, Bürger F, Okun JG, Hansikova H, Thiel C
Molecular genetics and metabolism 2023 Jul;139(3):107610
Molecular genetics and metabolism 2023 Jul;139(3):107610
Exploring the glycolytic cross-talk genes between inflammatory bowel disease and colorectal cancer.
Ye C, Huang Y, Gao Y, Zhu S, Yuan J
Functional & integrative genomics 2023 Jul 10;23(3):230
Functional & integrative genomics 2023 Jul 10;23(3):230
N-Glycosylation Deficiency Reduces the Activation of Protein C and Disrupts Endothelial Barrier Integrity.
Pascreau T, Saller F, Bianchini EP, Lasne D, Bruneel A, Reperant C, Foulquier F, Denis CV, De Lonlay P, Borgel D
Thrombosis and haemostasis 2022 Sep;122(9):1469-1478
Thrombosis and haemostasis 2022 Sep;122(9):1469-1478
Fatal outcome after heart surgery in PMM2-CDG due to a rare homozygous gene variant with double effects.
Görlacher M, Panagiotou E, Himmelreich N, Hüllen A, Beedgen L, Dimitrov B, Geiger V, Zielonka M, Peters V, Strahl S, Vázquez-Jiménez J, Kerst G, Thiel C
Molecular genetics and metabolism reports 2020 Dec;25:100673
Molecular genetics and metabolism reports 2020 Dec;25:100673
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S, Sam FS, DiPrimio N, Preston G, Verheijen J, Murthy K, Parton Z, Tsang H, Lao J, Morava E, Perlstein EO
Disease models & mechanisms 2019 Nov 11;12(11)
Disease models & mechanisms 2019 Nov 11;12(11)
Novel variants and clinical symptoms in four new ALG3-CDG patients, review of the literature, and identification of AAGRP-ALG3 as a novel ALG3 variant with alanine and glycine-rich N-terminus.
Himmelreich N, Dimitrov B, Geiger V, Zielonka M, Hutter AM, Beedgen L, Hüllen A, Breuer M, Peters V, Thiemann KC, Hoffmann GF, Sinning I, Dupré T, Vuillaumier-Barrot S, Barrey C, Denecke J, Kölfen W, Düker G, Ganschow R, Lentze MJ, Moore S, Seta N, Ziegler A, Thiel C
Human mutation 2019 Jul;40(7):938-951
Human mutation 2019 Jul;40(7):938-951
Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2.
Andreotti G, Monti MC, Citro V, Cubellis MV
PloS one 2015;10(10):e0139882
PloS one 2015;10(10):e0139882
Lack of phosphomannomutase 2 affects Xenopus laevis morphogenesis and the non-canonical Wnt5a/Ror2 signalling.
Himmelreich N, Kaufmann LT, Steinbeisser H, Körner C, Thiel C
Journal of inherited metabolic disease 2015 Nov;38(6):1137-46
Journal of inherited metabolic disease 2015 Nov;38(6):1137-46
Changes in the striatal proteome of YAC128Q mice exhibit gene-environment interactions between mutant huntingtin and manganese.
Wegrzynowicz M, Holt HK, Friedman DB, Bowman AB
Journal of proteome research 2012 Feb 3;11(2):1118-32
Journal of proteome research 2012 Feb 3;11(2):1118-32
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HepG2 cells were subjected to SDS PAGE followed by western blot with 10666-1-AP(PMM2 antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The PMM2 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human PMM2. This antibody recognizes human,mouse,rat antigen. The PMM2 antibody has been validated for the following applications: ELISA, IHC, WB analysis.
